JP2010523717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523717A5 JP2010523717A5 JP2010503257A JP2010503257A JP2010523717A5 JP 2010523717 A5 JP2010523717 A5 JP 2010523717A5 JP 2010503257 A JP2010503257 A JP 2010503257A JP 2010503257 A JP2010503257 A JP 2010503257A JP 2010523717 A5 JP2010523717 A5 JP 2010523717A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- independently
- ring
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 47
- 125000005842 heteroatoms Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 239000000178 monomer Substances 0.000 claims description 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 12
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 12
- 125000004429 atoms Chemical group 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000005418 aryl aryl group Chemical group 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000004419 alkynylene group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000006270 aryl alkenylene group Chemical group 0.000 claims description 6
- 125000000732 arylene group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 150000002829 nitrogen Chemical group 0.000 claims description 6
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 Etoposide Drugs 0.000 claims description 3
- 102000007193 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 3
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 claims description 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 3
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 3
- 102000004965 antibodies Human genes 0.000 claims description 3
- 108090001123 antibodies Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 206010003816 Autoimmune disease Diseases 0.000 claims description 2
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims description 2
- 102100013714 DIABLO Human genes 0.000 claims description 2
- 101710002761 DIABLO Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- -1 TNF- [alpha] Proteins 0.000 claims 1
- 102100009534 TNF Human genes 0.000 description 3
- 0 CC[C@](C[C@](CCCC([C@]1NC([C@](C)NC)=CCCC1(C)C)=O)C(N[C@]1c2ccccc2CCC1)=O)N1N=CC*C(CCCC(N)=CN([C@@](C[C@]2C(N[C@](CCC3)c4c3cccc4)=O)CN2C([C@](C(C)(C)C)NC([C@](C)NC)=N)=O)N)=C1 Chemical compound CC[C@](C[C@](CCCC([C@]1NC([C@](C)NC)=CCCC1(C)C)=O)C(N[C@]1c2ccccc2CCC1)=O)N1N=CC*C(CCCC(N)=CN([C@@](C[C@]2C(N[C@](CCC3)c4c3cccc4)=O)CN2C([C@](C(C)(C)C)NC([C@](C)NC)=N)=O)N)=C1 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- YPTWSOJPLMWQMX-IBGYOADYSA-N C[C@@H](C(N[C@@H](C(C)(C)C)C(N(CC(C1)/C=N/C(c2cc(N)cc(C(N[C@@H](C[C@H]3C(/N=C\C4c5ccccc5CCC4)=O)CN3C([C@H](C(C)(C)C)NC(C(C)NC)=O)=O)=O)c2)=O)[C@@H]1C(N[C@H]1c2ccccc2CCC1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C(C)(C)C)C(N(CC(C1)/C=N/C(c2cc(N)cc(C(N[C@@H](C[C@H]3C(/N=C\C4c5ccccc5CCC4)=O)CN3C([C@H](C(C)(C)C)NC(C(C)NC)=O)=O)=O)c2)=O)[C@@H]1C(N[C@H]1c2ccccc2CCC1)=O)=O)=O)NC YPTWSOJPLMWQMX-IBGYOADYSA-N 0.000 description 1
- CJGPODZBXAXSQQ-CRJUXLEGSA-N C[C@@H](C(N[C@@H](C(C)(C)C)C(N(CC(C1)/C=N\C(C(CC2C3)(C4)CC3CC24C(N[C@@H](C[C@H]2C(N[C@H](CCC3)c4c3cccc4)=O)CN2C([C@H](C(C)(C)C)NC([C@H](C)NC)=O)=O)=O)=O)[C@@H]1C(N[C@H]1c2ccccc2CCC1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C(C)(C)C)C(N(CC(C1)/C=N\C(C(CC2C3)(C4)CC3CC24C(N[C@@H](C[C@H]2C(N[C@H](CCC3)c4c3cccc4)=O)CN2C([C@H](C(C)(C)C)NC([C@H](C)NC)=O)=O)=O)=O)[C@@H]1C(N[C@H]1c2ccccc2CCC1)=O)=O)=O)NC CJGPODZBXAXSQQ-CRJUXLEGSA-N 0.000 description 1
- JPHUVEPVDWCUHS-NLUXXOGOSA-N C[C@@H](C(N[C@@H](C(C)(C)C)C(N(C[C@H](C1)NCc2ccc(CN[C@@H](C[C@H]3C(N[C@H](CCC4)c5c4cccc5)=O)CN3C([C@H](C(C)(C)C)NC([C@H](C)NC)=O)=O)cc2)[C@@H]1C(N[C@H]1C2C=CC=CC2CCC1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C(C)(C)C)C(N(C[C@H](C1)NCc2ccc(CN[C@@H](C[C@H]3C(N[C@H](CCC4)c5c4cccc5)=O)CN3C([C@H](C(C)(C)C)NC([C@H](C)NC)=O)=O)cc2)[C@@H]1C(N[C@H]1C2C=CC=CC2CCC1)=O)=O)=O)NC JPHUVEPVDWCUHS-NLUXXOGOSA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91147207P | 2007-04-12 | 2007-04-12 | |
US60/911,472 | 2007-04-12 | ||
US95249307P | 2007-07-27 | 2007-07-27 | |
US60/952,493 | 2007-07-27 | ||
PCT/US2008/060140 WO2008128121A1 (en) | 2007-04-12 | 2008-04-11 | Smac mimetic dimers and trimers useful as anti-cancer agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010523717A JP2010523717A (ja) | 2010-07-15 |
JP2010523717A5 true JP2010523717A5 (US07794700-20100914-C00152.png) | 2012-02-09 |
JP5454943B2 JP5454943B2 (ja) | 2014-03-26 |
Family
ID=39864357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010503257A Expired - Fee Related JP5454943B2 (ja) | 2007-04-12 | 2008-04-11 | 抗癌剤として有用なsmac模倣二量体及び三量体 |
Country Status (10)
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
CA2598995C (en) * | 2005-02-25 | 2014-07-15 | Stephen M. Condon | Dimeric iap inhibitors |
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
BRPI0617751A2 (pt) | 2005-10-25 | 2011-08-02 | Aegera Therapeutics Inc | compostos de ligação do domìnio iap bir |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US7985735B2 (en) * | 2006-07-24 | 2011-07-26 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
US20100113326A1 (en) * | 2006-07-24 | 2010-05-06 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP2049524A2 (en) * | 2006-07-24 | 2009-04-22 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法 |
JP2010526834A (ja) | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規ペプチド阻害剤 |
US20110177060A1 (en) * | 2008-09-19 | 2011-07-21 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
EP2367824B1 (en) * | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
SG175144A1 (en) * | 2009-04-15 | 2011-11-28 | Abbott Lab | Anti-viral compounds |
JP5530514B2 (ja) | 2009-06-11 | 2014-06-25 | アッヴィ・バハマズ・リミテッド | Hcv感染を治療するための抗ウィルス化合物 |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
EP2784076A1 (en) * | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9603889B2 (en) * | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CN104710510A (zh) * | 2013-12-12 | 2015-06-17 | 深圳先进技术研究院 | Smac蛋白二聚拟合物及其鉴定方法 |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CA2950911C (en) | 2014-06-04 | 2023-10-10 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
KR20230119040A (ko) | 2015-01-20 | 2023-08-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법 |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
JP6953435B2 (ja) * | 2016-05-09 | 2021-10-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二量体化合物 |
MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
KR102173464B1 (ko) | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
KR102564201B1 (ko) | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | EESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED METHOD OF USE |
EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
CA3095494C (en) | 2018-04-04 | 2023-11-07 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
AU2020252216A1 (en) | 2019-04-05 | 2021-11-04 | Hepagene Therapeutics (HK) Limited | Bivalent antagonists of inhibitors of apoptosis proteins |
US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
MX2022008874A (es) | 2020-01-20 | 2022-08-11 | Astrazeneca Ab | Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer. |
WO2022164900A1 (en) * | 2021-01-27 | 2022-08-04 | Unm Rainforest Innovations | Pyrazole and pyrazoline-containing peptides, high throughput click libraries, and methods |
EP4308095A1 (en) | 2021-03-15 | 2024-01-24 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
WO2023239422A2 (en) | 2021-10-22 | 2023-12-14 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5387584A (en) | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
US5932566A (en) | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
SE9603466D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
US6916846B2 (en) * | 2000-05-12 | 2005-07-12 | Merck & Co. Inc. | Coumermycin analogs as chemical dimerizers of chimeric proteins |
CN101928288B (zh) | 2000-11-02 | 2013-09-11 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
CA2491041A1 (en) * | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Hsp90-저해제로서의 신규 헤테로시클릭 화합물 |
JP4674231B2 (ja) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 2量体小分子アポトーシス増強剤 |
EP1740173A4 (en) | 2004-03-23 | 2009-05-27 | Genentech Inc | AZABICYCLOOCTAN IAP INHIBITORS |
JP4691549B2 (ja) | 2004-04-07 | 2011-06-01 | ノバルティス アーゲー | Iapの阻害剤 |
KR100984459B1 (ko) | 2004-07-02 | 2010-09-29 | 제넨테크, 인크. | Iap의 억제제 |
CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
ATE477254T1 (de) | 2004-12-20 | 2010-08-15 | Genentech Inc | Pyrrolidine als inhibitoren von iap |
CA2598995C (en) * | 2005-02-25 | 2014-07-15 | Stephen M. Condon | Dimeric iap inhibitors |
JP4954983B2 (ja) * | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
-
2008
- 2008-04-11 MX MX2009010667A patent/MX2009010667A/es active IP Right Grant
- 2008-04-11 CN CN200880011260.1A patent/CN101668426B/zh not_active Expired - Fee Related
- 2008-04-11 US US12/101,733 patent/US8642554B2/en not_active Expired - Fee Related
- 2008-04-11 NZ NZ580313A patent/NZ580313A/en not_active IP Right Cessation
- 2008-04-11 BR BRPI0810178-7A patent/BRPI0810178A2/pt not_active IP Right Cessation
- 2008-04-11 WO PCT/US2008/060140 patent/WO2008128121A1/en active Application Filing
- 2008-04-11 CA CA2684169A patent/CA2684169C/en not_active Expired - Fee Related
- 2008-04-11 JP JP2010503257A patent/JP5454943B2/ja not_active Expired - Fee Related
- 2008-04-11 AU AU2008240153A patent/AU2008240153B2/en not_active Ceased
- 2008-04-11 EP EP08745697.6A patent/EP2079309B1/en not_active Withdrawn - After Issue
-
2014
- 2014-01-16 US US14/156,522 patent/US20140127155A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010523717A5 (US07794700-20100914-C00152.png) | ||
JP2009530424A5 (US07794700-20100914-C00152.png) | ||
CA2684169A1 (en) | Smac mimetic dimers and trimers useful as anti-cancer agents | |
ES2670571T3 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
TW201625626A (zh) | 作爲蛋白質激酶抑制劑之胺基噠嗪酮化合物 | |
JP2019514426A5 (US07794700-20100914-C00152.png) | ||
JP2007511527A5 (US07794700-20100914-C00152.png) | ||
IL302338A (en) | ENPP1 inhibitors and their use for cancer treatment | |
HU229076B1 (en) | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties | |
JP2007511535A5 (US07794700-20100914-C00152.png) | ||
JPH11500427A (ja) | シクロプロピルピロロインドール−オリゴペプチド抗癌剤 | |
RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
JP2008517983A5 (US07794700-20100914-C00152.png) | ||
JP2009524696A5 (US07794700-20100914-C00152.png) | ||
JP2010524932A5 (US07794700-20100914-C00152.png) | ||
RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
JP2011500725A5 (US07794700-20100914-C00152.png) | ||
RU2009135621A (ru) | Хинолиновые производные для лечения воспалительных заболеваний | |
JP2007530694A5 (US07794700-20100914-C00152.png) | ||
CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
CN115068484A (zh) | 免疫相关和炎性疾病的治疗 | |
JPWO2010027005A1 (ja) | 置換アミン誘導体及びこれを有効成分とする医薬組成物 |